Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 50,600 shares, a drop of 29.8% from the February 13th total of 72,100 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is currently 1.2 days.

Hedge Funds Weigh In On Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC raised its stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 200,221 shares of the company’s stock after purchasing an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned 6.67% of Kiora Pharmaceuticals worth $661,000 as of its most recent filing with the Securities and Exchange Commission. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX traded down $0.01 on Friday, reaching $3.24. 3,722 shares of the stock traded hands, compared to its average volume of 33,125. Kiora Pharmaceuticals has a 12 month low of $2.91 and a 12 month high of $6.48. The stock’s 50-day moving average price is $3.56 and its 200-day moving average price is $3.51.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.